The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

OCTOBER 19, 2020

.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. among adults 65 years of age or older.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

SEPTEMBER 30, 2021

An expert review by a world group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the overall population aren’t appropriate at this stage within the pandemic.

Vaccine 52

Vaccine Immune Response Disease International 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. These epitopes could then be used in a vaccine to train T cells, providing protective immunity.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

JANUARY 31, 2021

Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Glenn, M.D.,

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

OCTOBER 14, 2020

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., About TNX-1800. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. Yet, the recent COVID-19 pandemic highlighted the obstacles that are inherent today in the development of vaccines. Stabilizers play a crucial role in maintaining the vaccine's potency and integrity throughout its shelf life.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

The Pharma Data

NOVEMBER 16, 2020

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens. However, most of these peptides may also be presented by normal cells.

Engineering 110

Engineering DNA Virus Immune Response 110

DrugBaron

APRIL 13, 2020

While lockdowns may slow the rate of viral transmission in the short term, our longer time battle with the virus will depend on how quickly the population develops sufficient immunity (whether through natural exposure or a vaccine, once one becomes available). Selecting an appropriate antigen mix, however, is probably the easier part.

Immune Response 100

Immune Response Virus Vaccine Production 100

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) advisory panel in regard to the COVID-19 vaccine from Moderna. The Vaccines and Related Biological Products Advisory Committee will be determining whether the product should be authorized for emergency use, according to CNBC. ET, according to a draft of the agenda.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

MARCH 3, 2022

The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

MAY 15, 2023

The vaccine candidate demonstrated non-inferiority in primary endpoints for five Neisseria meningitidis serogroups (A, B, C, W, and Y) compared to two doses of Bexsero (meningococcal group B vaccine) and one dose of Menveo (meningococcal group A, C, W-135, and Y conjugate vaccine) in 10–25-year-olds.

Vaccine 40

Vaccine Immune Response Licensing Licensing 40

The Pharma Data

JUNE 18, 2021

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. NEW YORK–(BUSINESS WIRE)– Pfizer Inc. Jansen, Ph.D.,

Vaccine 52

Vaccine FDA Approval FDA Disease 52

Codon

APRIL 23, 2023

This newsletter’s format has shifted again, as I try to figure out the most enticing way to present this stuff. Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. Promising new malaria vaccine for kids approved in Ghana. Associated Press.

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

This newsletter’s format has shifted again, as I try to figure out the most enticing way to present this stuff. Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. Promising new malaria vaccine for kids approved in Ghana. Associated Press.

Vaccine 52

Vaccine DNA Virus Engineering 52

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

Agency IQ

MARCH 7, 2024

Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) weighed in on strains for seasonal influenza vaccines for the Northern hemisphere 2024-2025 season.

Vaccine 40

Vaccine FDA Virus Licensing 40

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

JANUARY 5, 2021

Food and Drug Administration said Monday that any American who gets the Moderna or Pfizer coronavirus vaccines must get two full doses, despite international debate on possible ways to stretch vaccine supply. vaccine effort just as the public is starting to trust the program, Dr. Anthony Fauci told The New York Times.

Vaccine 52

Vaccine FDA Virus Immune Response 52

DrugBank

MAY 6, 2024

This category encompasses a broad spectrum of treatments including vaccines, blood components, gene therapies, and more, each tailored to combat diseases in highly specific ways. The production, delivery, and practical application of biologics all present hurdles that need addressing if these therapies are to achieve their full promise.

FDA Approval 96

FDA Approval Therapies Treatment Clinical Trials 96

Drug Target Review

OCTOBER 2, 2023

Immunopeptidomics is a rapidly expanding field at the intersection of immunology and proteomics that focuses on the identification and characterization of peptides presented by major histocompatibility complex (MHC) molecules, also known as the human leukocyte antigen (HLA), on cell surfaces.

Immune Response 106

Immune Response Vaccine Disease Research 106

The Pharma Data

JANUARY 29, 2021

January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints.

Vaccine 40

Vaccine Trials Pharmaceutical Companies Clinical Trials 40

Drug Target Review

JULY 11, 2023

In simple terms, our immune system is divided into innate and adaptive responses – the innate being the first line of defence, and the adaptive responds to specific challenges by modifying the body’s immune response in a tailored fashion.

Disease 75

Disease RNA Small Molecule Clinical Development 75

Chemical Biology and Drug Design

APRIL 28, 2023

Leishmania infection may arise from virulence factors; they are treatable with medications or vaccinations more promptly and might greatly shorten the duration of treatment.

Immune Response 100

Immune Response Vaccine Treatment Disease 100

Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

JUNE 30, 2021

Dr Karin Moestl, Vice President of the ABCD , presented the 2021 Young Scientist Award to the two winners during the ISFM ( International Society of Feline Medicine ) World Feline Congress 2021 , held virtually from June 25 to 27, 2021. . We warmly congratulate this year’s winners.”

Immune Response 52

Immune Response Virus Disease Doctors 52

Agency IQ

JUNE 9, 2023

However, even the most innovative in vitro assays still present major limitations when it comes to fully understanding and assessing the risks of a product. Cell and gene therapy products, adjuvanted vaccines, and blood products all fall outside the scope. increased tumor promotion or metastasis due to immunosuppression).

FDA 40

FDA Science Small Molecule Immune Response 40

SugarCone Biotech

MAY 28, 2019

This broader and still evolving contextual framework will impact immunotherapy drug development across the immune checkpoint field, the tumor vaccine space, innate immune approaches, the T-cell-directed biologics, and cellular therapies. But first, these new papers are gorgeous: The study presented by Petitprez et al.

Immune Response 52

Immune Response Therapies Production Vaccine 52

The Pharma Data

APRIL 28, 2021

Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis. These data will be presented as a late-breaking abstract oral presentation at AAD VMX 2021. Abstracts to be presented at AAD VMX 2021.

Disease 40

Disease Trials Laboratories Clinical Trials 40

Drug Target Review

MARCH 1, 2024

In this study , we demonstrated that AMP immunotherapy can boost TCR-T cell therapy by acting directly in the lymph nodes to promote the coordination of tumour-specific T cell responses by antigen presenting cells. This combination approach resulted in durable anti-tumour T cell responses and tumour eradication.

Immune Response 106

Immune Response Therapies Vaccine Small Molecule 106